Q2 2025 Beiersdorf AG Earnings Call Transcript
Key Points
- Beiersdorf AG (BDRFF) achieved a solid performance in the first half of 2025 despite challenging market conditions, with a group organic sales growth of 2.1%.
- The Derma business continued its growth trajectory, achieving outstanding double-digit sales growth of 12.2% in the first half of 2025.
- The launch of the anti-age ingredient Epicelline under Eucerin has been a success, and its upcoming launch under Nivea is expected to boost sales significantly in the second half of 2025.
- The Healthcare business, including Hansaplast and Elastoplast brands, delivered strong organic sales growth of 8.4%, driven by innovation such as the Second Skin Protection plaster.
- Beiersdorf AG (BDRFF) is optimistic about the second half of 2025, with a strong innovation pipeline and plans to launch Nivea Epigenetic serum in 30 countries by the end of the year.
- Nivea's performance fell below expectations in the first half of 2025, with only 1% organic growth, impacted by slower markets and a high prior year comparison base.
- The luxury brand La Prairie experienced a sales decline of 10.7% in the first half of 2025, with particular softness in the US and travel retail markets.
- The mass market did not grow as anticipated, with emerging markets in Eastern Europe slowing significantly due to economic uncertainties and cautious consumer spending.
- Beiersdorf AG (BDRFF) faced increased competition from local brands, which are often cheaper and based on simple ingredient stories.
- The EBIT margin guidance for the Consumer segment was reduced to 20 basis points above last year's level, down from the previous 50 basis points guidance, indicating pressure on profitability.
Ladies and gentlemen, welcome to the Beiersdorf H1 results 2025 conference call. I am Valentina, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to Christopher Sheldon, Head of Investor Relations. Please go ahead.
Good morning, everyone, and thank you for joining us this morning for the presentation of our first half year results 2025. I'm here with our CEO, Vincent Warnery; and our CFO, Astrid Hermann. As always, we will start with the presentation of our results, followed by a Q&A session.
And with that, I would like to hand over to Vincent.
Thank you, Christopher. Good morning, everyone, and thank you for joining today's conference call. Astrid and I will now present
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
